Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor

Cancer Research

Volumn 61, Issue 14, 2001, Pages 5349-5354

  Mishima, Kazuhiko ^a   Johns, Terrance G ^b   Luwor, Rodney B ^b   Scott, Andrew M ^b   Stockert, Elisabeth ^c   Jungbluth, Achim A ^c   Ji, Xiang Dong ^d   Suvarna, Padma ^d   Voland, Joseph R ^d   Old, Lloyd J ^c   Su Huang, H J ^a   Cavenee, Webster K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AUSTIN HOSPITAL   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^d BD Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; PROTEIN BCL X; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CROSS REACTION; DOWN REGULATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL DIVISION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035878746     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Immunotherapy for cancer
2. An overview of monoclonal antibody therapy of cancer
3. Monoclonal antibody therapy for solid tumors
4. Monoclonal antibodies to growth factors and growth factor receptors: Their diagnostic and therapeutic potential in brain tumors
5. Therapeutic application of anti-growth factor receptor antibodies
6. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
7. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
8. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
9. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
10. Clinical trials of Herceptin(R) (trastuzumab)
11. Epidermal growth factor-related peptides and their receptors in human malignancies
12. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
13. Role of an anti-epidermal growth factor receptor in treating cancer
14. A Phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
15. The class III variant of the epidermal growth factor receptor (EGFRvIII): Characterization and utilization as an immunotherapeutic target
16. Structural alterations of the epidermal growth factor receptor gene in human gliomas
17. Monoclonal antibody therapy of human gliomas: Current status and future approaches
18. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas
19. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
20. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer
21. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
22. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
23. Expression of a tumor-specific mutant epidermal growth factor receptor mediates glioma cell invasion in vivo
24. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors
25. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
26. L and caspase-3-like proteases
27. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
28. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
29. Aberrant receptor signaling in human malignant gliomas: Mechanisms and therapeutic implications
30. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA
31. Unarmed tumor-specific monoclonal antibody effectively treats brain tumors
32. Monoclonal antibody drug conjugates in the treatment of cancer
33. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
34. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
35. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
36. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts